vs
dLocal Ltd（DLO）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
dLocal Ltd的季度营收约是Orthofix Medical Inc.的1.5倍（$337.9M vs $219.9M），dLocal Ltd净利率更高（16.5% vs -1.0%，领先17.5%），dLocal Ltd同比增速更快（65.2% vs 2.0%），dLocal Ltd自由现金流更多（$99.8M vs $16.8M）
dLocal是一家总部位于乌拉圭的金融科技企业，专注于提供跨境支付解决方案，搭建全球商户与新兴市场之间的支付链路，助力国际商户顺畅接入新兴市场本地支付网络，高效开展跨境业务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
DLO vs OFIX — 直观对比
营收规模更大
DLO
是对方的1.5倍
$219.9M
营收增速更快
DLO
高出63.3%
2.0%
净利率更高
DLO
高出17.5%
-1.0%
自由现金流更多
DLO
多$83.0M
$16.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $337.9M | $219.9M |
| 净利润 | $55.6M | $-2.2M |
| 毛利率 | 34.3% | 71.1% |
| 营业利润率 | 18.6% | 0.2% |
| 净利率 | 16.5% | -1.0% |
| 营收同比 | 65.2% | 2.0% |
| 净利润同比 | 87.3% | 92.4% |
| 每股收益（稀释后） | $0.18 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DLOOFIX
| Q4 25 | $337.9M | $219.9M | ||
| Q3 25 | $282.5M | $205.6M | ||
| Q2 25 | — | $203.1M | ||
| Q1 25 | — | $193.6M | ||
| Q4 24 | $204.5M | $215.7M | ||
| Q3 24 | $185.8M | $196.6M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $188.6M |
净利润DLOOFIX
| Q4 25 | $55.6M | $-2.2M | ||
| Q3 25 | $141.3M | $-22.8M | ||
| Q2 25 | — | $-14.1M | ||
| Q1 25 | — | $-53.1M | ||
| Q4 24 | $29.7M | $-29.1M | ||
| Q3 24 | $90.8M | $-27.4M | ||
| Q2 24 | — | $-33.4M | ||
| Q1 24 | — | $-36.0M |
毛利率DLOOFIX
| Q4 25 | 34.3% | 71.1% | ||
| Q3 25 | 36.5% | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | 40.9% | 69.0% | ||
| Q3 24 | 42.1% | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率DLOOFIX
| Q4 25 | 18.6% | 0.2% | ||
| Q3 25 | 19.7% | -8.3% | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | 20.7% | -5.3% | ||
| Q3 24 | 22.1% | -9.6% | ||
| Q2 24 | — | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率DLOOFIX
| Q4 25 | 16.5% | -1.0% | ||
| Q3 25 | 50.0% | -11.1% | ||
| Q2 25 | — | -6.9% | ||
| Q1 25 | — | -27.4% | ||
| Q4 24 | 14.5% | -13.5% | ||
| Q3 24 | 48.9% | -13.9% | ||
| Q2 24 | — | -16.8% | ||
| Q1 24 | — | -19.1% |
每股收益（稀释后）DLOOFIX
| Q4 25 | $0.18 | $-0.05 | ||
| Q3 25 | $0.17 | $-0.57 | ||
| Q2 25 | — | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | $0.09 | $-0.76 | ||
| Q3 24 | $0.09 | $-0.71 | ||
| Q2 24 | — | $-0.88 | ||
| Q1 24 | — | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $719.9M | $82.0M |
| 总债务越低越好 | $86.7M | — |
| 股东权益账面价值 | $569.4M | $450.0M |
| 总资产 | $1.5B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资DLOOFIX
| Q4 25 | $719.9M | $82.0M | ||
| Q3 25 | $604.5M | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | $425.2M | $83.2M | ||
| Q3 24 | $560.5M | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务DLOOFIX
| Q4 25 | $86.7M | — | ||
| Q3 25 | $63.1M | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $39.8M | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益DLOOFIX
| Q4 25 | $569.4M | $450.0M | ||
| Q3 25 | $504.7M | $442.5M | ||
| Q2 25 | — | $458.3M | ||
| Q1 25 | — | $458.3M | ||
| Q4 24 | $489.0M | $503.1M | ||
| Q3 24 | $457.0M | $525.9M | ||
| Q2 24 | — | $546.0M | ||
| Q1 24 | — | $570.3M |
总资产DLOOFIX
| Q4 25 | $1.5B | $850.6M | ||
| Q3 25 | $1.4B | $832.6M | ||
| Q2 25 | — | $837.2M | ||
| Q1 25 | — | $823.1M | ||
| Q4 24 | $1.2B | $893.3M | ||
| Q3 24 | — | $867.9M | ||
| Q2 24 | — | $882.0M | ||
| Q1 24 | — | $906.0M |
负债/权益比DLOOFIX
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.12× | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 0.08× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $100.4M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $99.8M | $16.8M |
| 自由现金流率自由现金流/营收 | 29.5% | 7.6% |
| 资本支出强度资本支出/营收 | 0.2% | 4.9% |
| 现金转化率经营现金流/净利润 | 1.80× | — |
| 过去12个月自由现金流最近4个季度 | $378.7M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流DLOOFIX
| Q4 25 | $100.4M | $27.7M | ||
| Q3 25 | $315.0M | $12.4M | ||
| Q2 25 | — | $11.6M | ||
| Q1 25 | — | $-18.4M | ||
| Q4 24 | $-141.1M | $23.7M | ||
| Q3 24 | $108.3M | $11.7M | ||
| Q2 24 | — | $9.0M | ||
| Q1 24 | — | $-18.6M |
自由现金流DLOOFIX
| Q4 25 | $99.8M | $16.8M | ||
| Q3 25 | $313.4M | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | $-141.6M | $15.2M | ||
| Q3 24 | $107.1M | $6.3M | ||
| Q2 24 | — | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率DLOOFIX
| Q4 25 | 29.5% | 7.6% | ||
| Q3 25 | 110.9% | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | -69.2% | 7.0% | ||
| Q3 24 | 57.6% | 3.2% | ||
| Q2 24 | — | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度DLOOFIX
| Q4 25 | 0.2% | 4.9% | ||
| Q3 25 | 0.6% | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | 0.2% | 4.0% | ||
| Q3 24 | 0.7% | 2.7% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | 5.6% |
现金转化率DLOOFIX
| Q4 25 | 1.80× | — | ||
| Q3 25 | 2.23× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -4.75× | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DLO
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
